中关村：胞磷胆碱钠注射液一致性评价申报获受理

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the consistency evaluation application of sodium cytidine injection [1] Group 1 - The product under application is indicated for: 1) cerebral blood supply disorders during acute and subacute phases caused by thrombosis or vascular rupture 2) conditions resulting from head trauma due to impact [1]